Trevena, Inc. (TRVN): Price and Financial Metrics
TRVN Price/Volume Stats
| Current price | $0.41 | 52-week high | $3.28 |
| Prev. close | $0.38 | 52-week low | $0.30 |
| Day low | $0.37 | Volume | 114,900 |
| Day high | $0.42 | Avg. volume | 180,898 |
| 50-day MA | $0.49 | Dividend yield | N/A |
| 200-day MA | $0.65 | Market Cap | 7.49M |
TRVN Stock Price Chart Interactive Chart >
Trevena, Inc. (TRVN) Company Bio
Trevena Inc. is a clinical stage biopharmaceutical company focused on the discovery, development, and intent to commercialize therapeutics for G protein coupled receptors. The company was founded in 2007 and is based in King of Prussia, Pennsylvania.
Latest TRVN News From Around the Web
Below are the latest news stories about TREVENA INC that investors may wish to consider to help them evaluate TRVN as an investment opportunity.
Trevena Announces the Closing of $4 Million Concurrent Private Placement and Warrant ExerciseCHESTERBROOK, Pa., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (“Trevena” or the “Company”) (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it has closed its previously announced offering for the issuance and sale of 2,779,906 shares of common stock (or pre-funded warrants in lieu thereof) of Trevena and warrants to purchase up to an aggregate of 2,77 |
Trevena Inc. Announces $4 Million Concurrent Private Placement and Warrant ExerciseCHESTERBROOK, Pa., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Trevena Inc. (“Trevena” or the “Company”) (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it has entered into definitive agreements for the issuance and sale of 2,779,906 shares of common stock (or pre-funded warrants in lieu thereof) of Trevena and warrants to purchase up to an aggregate of 2,779,906 s |
Trevena Announces TRV045 Presentation at the American College of Neuropsychopharmacology 62nd Annual Meeting-- Presentation highlighted promising results of TRV045 in nonclinical models of neuropathic pain including mechanical and cold-stimulus evoked nociceptive pain in a dose-related manner TRV045 selectively targets the S1P1 receptor without associated lymphopenia -- CHESTERBROOK, Pa., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders |
Trevena Awarded OLINVYK Agreement with Premier, Inc.CHESTERBROOK, Pa., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Trevena Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, has been awarded a national group purchasing agreement for OLINVYK with Premier, Inc. Effective December 1, 2023, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for OLINVYK. P |
Trevena Announces Acceptance of Abstract Examining the Use of OLINVYK in Patients with Acute Burn InjuriesResults from investigator-initiated RELIEVE study will be presented at the 2024 American Burn Association (ABA) Annual Meeting in Chicago from April 9th-12thCHESTERBROOK, Pa., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, announced today the acceptance of an abstract based on the pRospective, case-controlled Evaluation of oLIc |
TRVN Price Returns
| 1-mo | -7.51% |
| 3-mo | -35.56% |
| 6-mo | -21.31% |
| 1-year | -33.98% |
| 3-year | -99.05% |
| 5-year | -98.90% |
| YTD | -43.22% |
| 2023 | -49.50% |
| 2022 | -90.18% |
| 2021 | -72.78% |
| 2020 | 154.49% |
| 2019 | 95.56% |
Continue Researching TRVN
Want to do more research on Trevena Inc's stock and its price? Try the links below:Trevena Inc (TRVN) Stock Price | Nasdaq
Trevena Inc (TRVN) Stock Quote, History and News - Yahoo Finance
Trevena Inc (TRVN) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...